CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 182 enrolled
Drug / intervention
OC-01 (varenicline) nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03636061
NCT03636061Phase 2Completed
CompareCT.gov

Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-1 Study)

Oyster Point Pharma, Inc.·interventional·Posted Aug 17, 2018·Updated Oct 25, 2021

In Brief

A Phase 2 clinical trial evaluating OC-01 (varenicline) nasal spray and Placebo (vehicle) nasal spray for Dry Eye Disease. Completed, enrolled 182 participants across 3 sites.

Detailed Summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 17, 2018
Enrollment StartAug 15, 2018
Primary CompletionSep 26, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.9 years ago

Interventions

OC-01 (varenicline) nasal spraydrug

OC-01 (varenicline) nasal spray

Placebo (vehicle) nasal spraydrug

Placebo